Clinical trial
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem…
NCT00038818 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00038818 |
|---|---|
| Title | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation |
| Official title | CD8 Depleted Donor Lymphocyte Infusions for Patients With Relapse Or Residual Disease Following Allogeneic Stem Cell Transplantation |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eligix |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia |
| Intervention type | Biological |
| Interventions | CD8 Depleted Donor Lymphocyte |
| Enrollment | 3 |
| Start date | May 1, 2001 |
| Primary completion | Dec 1, 2002 |
| Completion | Dec 1, 2002 |
| First posted | Jun 7, 2002 |
| Last update posted | Aug 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: